Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.
Camilleri M, Lembo AJ, Lavins BJ, MacDougall JE, Carson RT, Williams VSL, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J. 2015 Feb 3;3(1):53-62. doi: 10.1177/2050640614555946
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.